These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 7514855)

  • 1. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
    Gu Z; Gao Q; Fang H; Salomon H; Parniak MA; Goldberg E; Cameron J; Wainberg MA
    Antimicrob Agents Chemother; 1994 Feb; 38(2):275-81. PubMed ID: 7514855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
    Gu Z; Gao Q; Li X; Parniak MA; Wainberg MA
    J Virol; 1992 Dec; 66(12):7128-35. PubMed ID: 1279198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
    Gao Q; Gu Z; Parniak MA; Cameron J; Cammack N; Boucher C; Wainberg MA
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1390-2. PubMed ID: 8392313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.
    Gu Z; Fletcher RS; Arts EJ; Wainberg MA; Parniak MA
    J Biol Chem; 1994 Nov; 269(45):28118-22. PubMed ID: 7525567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene.
    Gu Z; Gao Q; Fang H; Parniak MA; Brenner BG; Wainberg MA
    Leukemia; 1994 Apr; 8 Suppl 1():S166-9. PubMed ID: 7512178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase.
    Zhang D; Caliendo AM; Eron JJ; DeVore KM; Kaplan JC; Hirsch MS; D'Aquila RT
    Antimicrob Agents Chemother; 1994 Feb; 38(2):282-7. PubMed ID: 7514856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.
    Boucher CA; Cammack N; Schipper P; Schuurman R; Rouse P; Wainberg MA; Cameron JM
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2231-4. PubMed ID: 7504909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.
    Schinazi RF; Lloyd RM; Nguyen MH; Cannon DL; McMillan A; Ilksoy N; Chu CK; Liotta DC; Bazmi HZ; Mellors JW
    Antimicrob Agents Chemother; 1993 Apr; 37(4):875-81. PubMed ID: 7684216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.
    Medlin HK; Zhu YQ; Remington KM; Phillips TR; North TW
    Antimicrob Agents Chemother; 1996 Apr; 40(4):953-7. PubMed ID: 8849258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.
    Smith RA; Remington KM; Lloyd RM; Schinazi RF; North TW
    J Virol; 1997 Mar; 71(3):2357-62. PubMed ID: 9032372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
    Cherry E; Slater M; Salomon H; Rud E; Wainberg MA
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2763-5. PubMed ID: 9420055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
    J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture.
    Lacey SF; Larder BA
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1428-32. PubMed ID: 7522429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals.
    Brindeiro R; Vanderborght B; Caride E; Correa L; Oravec RM; Berro O; Stuyver L; Tanuri A
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1674-80. PubMed ID: 10390221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
    Harrigan PR; Kinghorn I; Bloor S; Kemp SD; Nájera I; Kohli A; Larder BA
    J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.
    Eron JJ; Chow YK; Caliendo AM; Videler J; Devore KM; Cooley TP; Liebman HA; Kaplan JC; Hirsch MS; D'Aquila RT
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1480-7. PubMed ID: 7689822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
    Bazmi HZ; Hammond JL; Cavalcanti SC; Chu CK; Schinazi RF; Mellors JW
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1783-8. PubMed ID: 10858331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs.
    Gu Z; Arts EJ; Parniak MA; Wainberg MA
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2760-4. PubMed ID: 7535930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1.
    Salomon H; Belmonte A; Nguyen K; Gu Z; Gelfand M; Wainberg MA
    J Clin Microbiol; 1994 Aug; 32(8):2000-2. PubMed ID: 7527427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.